Latest Organic chemistry Stories
On April 3, 2013, OpiateCureBlog.com launched a public forum allowing former patients of retired physician Dr. Robert T. Cochran, the ability to communicate with one another. The goal of the forum is to help former patients of Dr. Cochran to find replacement care and new treatments for chronic pain and bipolar disorder. Nashville, TN (PRWEB) April 09, 2013 On April 3, 2013, OpiateCureBlog.com launched a public forum allowing former patients of retired physician Dr. Robert T. Cochran, the...
Is the era of targeted therapy for breast cancer at hand? It could be, said experts at the Lester and Sue Smith Breast Center at Baylor College of Medicine – at least for a certain population of women. In a report that appears online today in the Journal of Clinical Oncology, the researchers have shown that a subset of breast cancer patients who have tumors overexpressing a protein called the human epidermal growth factor receptor 2 (HER-2 positive) may benefit from a combination of...
The HYDROTHERM is a state of the art instrument brought to North America by Lab Synergy LLC. This system is designed to completely replace the Mojonnier Method, used by many for the extraction of fat with a mixture of ethyl ether and petroleum ether. Goshen, NY (PRWEB) April 08, 2013 The HYDROTHERM is a state of the art instrument brought to North America by Lab Synergy LLC. This system is designed to completely replace the Mojonnier Method, used by many for the extraction of fat with a...
NT-113 is an Irreversible, Selective Pan-ErbB Tyrosine Kinase Inhibitor with Significant Capacity to Cross Blood Brain Barrier MENLO PARK, Calif., April 8, 2013 /PRNewswire/ -- Preclinical data showing high potency, excellent pharmacokinetics and single-agent anti-cancer activity of NT-113, a novel irreversible Pan-ErbB Tyrosine Kinase Inhibitor under development by NewGen Therapeutics, was presented in a poster session today at the American Association of Cancer Research Meeting in...
New Once-Daily NSAID Indicated for Treatment of Postoperative Inflammation and Reduction of Ocular Pain Following Cataract Surgery MADISON, N.J., April 8, 2013 /PRNewswire/ -- Bausch + Lomb, the global eye health company, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for PROLENSA(TM) (bromfenac ophthalmic solution) 0.07 percent prescription eye drop, an innovative once-daily nonsteroidal anti-inflammatory...
WASHINGTON, April 8, 2013 /PRNewswire/ -- EG Ministry of Health recently met with Dr. Gloria B. Herndon of GB Group Global in the nation's capital as part of Equatorial Guinea's efforts to drastically raise its standards of health care. These endeavors include building a pharmaceutical manufacturing facility in EG, implementing pharmaceutical quality control and policies, and exploring the release of a new treatment (Low Dose Naltrexone) against cancer and HIV/AIDS. The purpose of...
WAYNE, N.J., April 8, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the New Drug Application (NDA) for its oral investigational compound riociguat has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent CTEPH after pulmonary endarterectomy (PEA) and pulmonary arterial hypertension (PAH). Both CTEPH and PAH are...
BOSTON, April 8, 2013 /PRNewswire/ -- scPharmaceuticals LLC today announced that it has entered into a strategic partnership and product development agreement with Sensile Medical Holding AG of Zug, Switzerland to develop an innovative new therapeutic option for patients with heart failure. The terms of the agreement were not disclosed. The drug-device combination uses the Sensile SenseCore technology in a wearable minipump that delivers the pharmaceutical drug product under the...
The Rottenstein Law Group, a Pradaxa law firm, acknowledges the study and publicizes its Pradaxa page, which illustrates in detail the options for those who believe their medication has harmed them. New York, NY (PRWEB) April 05, 2013 On its website, Boehringer Ingelheim markets* blood-thinner Pradaxa as 35 percent more effective at reducing stroke than warfarin. But a recent study** presented at a Joint Session of the Heart Rhythm Society and the American College of Cardiology in San...
Drugs Include Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate® CARY, N.C., April 5, 2013 /PRNewswire/ -- Covis Pharmaceuticals, Inc. announced an agreement today to distribute Nilandron(®) (nilutamide), Plaquenil(®) (hydroxychloroquine), Rilutek(®) (riluzole), Uroxatral(®) (alfuzosin hydrochloride) and Kayexalate(®) (sodium polystyrene sulfate) in the United States.The products cover a broad array of treatments and disease states: Nilandron is used to treat...
Latest Organic chemistry Reference Libraries
Organometallics is a peer-reviewed scientific journal published by the American Chemical Society. As of May 2012, the editor-in-chief is John A. Gladysz. Organometallics publishes records in one of the most active fields for organometallic, inorganic, organic, and materials chemists. Articles, communications, mini-reviews, and notes detail the synthesis, structure, bonding, chemical reactivity and reaction mechanisms, and applications of organometallic and organometalloidal compounds....
Synthetic Metals is a peer-reviewed scientific journal published by Elsevier. It covers all aspects of electronic polymers and electronic molecular materials. It is an international medium for the rapid publication of original research papers, short communications and subject reviews dealing with research on and applications of electronic polymers and electronic molecular materials including novel carbon architectures. Original manuscripts on chemical, electrochemical, electrical, photonic...
